CORTCorcept Therapeutics Incorporated
$121.12+50% 1Y
$121.12
$32.1552 weeks$123.53
The financials
Corcept Therapeutics Incorporated by the numbers
Corcept Therapeutics Incorporated (CORT) reported revenue of $256M in Q2 2026 (quarter ended Jun 30, 2026), up 32% from the same quarter a year earlier. That came with a gross margin of 98% and net income of $43M (17% of revenue). For the full year FY2025, revenue was $761M (+13% year on year) and net income $100M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $256M | $194M | +32% |
| Gross profit | $252M | $191M | +32% |
| Operating income | $41M | $27M | +55% |
| Net income | $43M | $35M | +22% |
| Diluted EPS | $0.36 | $0.29 | +24% |